

THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO USA, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL. SEE ALSO SECTION IMPORTANT INFORMATION BELOW.

InDex Pharmaceuticals ends the subscription period for the initial public offering in connection with listing on Nasdaq First North Tuesday, September 27

September 26, 2016 - Tomorrow Tuesday, September 27, the subscription period ends for InDex Pharmaceuticals Holding AB's (publ) (the "Company or the" InDex") new issue of shares of SEK 250 million. The issue also includes an overallotment option of 25 million.

InDex main owners SEB Venture Capital, Industrifonden and NeoMed Management have made significant subscription commitments in the issue of new shares, which through subscription commitments and guarantee commitments is guaranteed to 100 percent.

Monday, September 26 - 23:59 - is the last opportunity to subscribe through Avanza (<https://www.avanza.se/mina-sidor/erbjudanden/erbjudande.1473941622610.html>)

Tuesday, September 27 - 15:00 - is the last opportunity to subscribe through Aqurat (<http://aqurat.se/ladda-ner/>)

Tuesday, September 27 - 23:59 - is the last opportunity to subscribe through Nordnet (<https://www.nordnet.se/kampanjer/ipo/index.html>)

InDex has applied for the Company's shares of class B to be listed for trading on Nasdaq First North Stockholm. Provided that the application for listing is approved, the first day of trading is planned to occur on or about the 11th of October 2016.

The purpose of the offering - in addition to broadening the shareholder base - is to fund the upcoming Phase IIb study with the drug candidate cobitolimod.

A dedicated IPO page with information about the company and its operations, including the prospectus, as well as practical information on how to proceed in order to participate in the IPO is found at: www.investerarbreuet.se/index.

Stockholm Corporate Finance AB is financial advisor and Setterwalls Advokatbyrå is the legal advisor to the Company in connection with the Offer. Aqurat Fondkommission AB acts as the issuing agent in connection with the Offer. Nordnet Bank AB is acting as sales agent in connection with the Offer.

For more information:

Peter Zerhouni, CEO
08-508 847 35
peter.zerhouni@indexpharma.com

About InDex Pharmaceuticals

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.

Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. Main shareholders are SEB Venture Capital, Industrifonden and NeoMed Management. The Company's operations are mainly conducted through its subsidiary InDex Pharmaceuticals AB. For more information, please visit www.indexpharma.com.

About cobitolimod

Cobitolimod has a new type of mechanism of action. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis.

Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively.

In January 2016, WHO recommended the INN name cobitolimod. The substance is also known as Kappaproct® and DIMS0150.

IMPORTANT INFORMATION

This document has not been approved by any regulatory authority. The document is a press release and not a prospectus and investors should not subscribe for or purchase securities referred to in this document except on the basis of information contained in the prospectus that has been approved by the Swedish Financial Supervisory Authority and is available at the company's website. Distribution of this press release could in some jurisdictions be subject to restrictions according to law and recipients of this, or part of this, are required to inform themselves of, and comply with, such legal restrictions. Information in this press release should not constitute an offer to sell shares, or a solicitation of any offer to purchase shares, nor should any sale of the securities referred to herein be made, in any jurisdiction where such offer, solicitation of any offer to purchase, or sale would require preparing additional prospectus or other offering documents, or would not be lawful without registration or applicable exemptions from registering according to security acts in any such jurisdiction.

This press release neither constitutes, nor constitutes a part of, an offer or a solicitation of an offer to purchase or subscribe for securities in the United States. Securities referred to herein have not been, and will not be, registered in accordance with the American Securities Act of 1933 ("Securities Act"), and may not be offered or sold within the United States absent registration in accordance with the Securities Act, or an exemption therefrom. Securities referred to herein are not offered to the general public in the United States. Copies of this press release is not being made and may not be distributed or sent, in whole, or part, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States or to any other jurisdiction where the distribution respectively the issuance of this press release would be unlawful.